¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"chronic hypocomplementemic glomerulonephritis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • chronic lingual papillitis
    ¸¸¼ºÇô À¯µÎ¿°
  • chronic lupus erythematosus
    ¸¸¼º È«¹Ý¼º ·çǪ½º
  • chronic lymphocytic leukemia
    ¸¸¼º¸²ÇÁ±¸(¼º)¹éÇ÷º´(¡­Ï¹àõÛÜúìÜ»).
  • chronic lymphocytic leukemia
    ¸¸¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´
  • chronic lymphocytic leukemia
    ¸¸¼º¸²ÇÁ±¸(¼º)¹éÇ÷º´(?Ë´ËÛËÑÌ´ËÓ).
  • chronic lymphocytic leukemia=CLL
    ¸¸¼º¸²ÇÁ±¸¼º¹éÇ÷º´
  • chronic lymphocytosis
    ¸¸¼º ¸²ÇÁ±¸Áõ°¡Áõ
  • chronic mastoiditis
    ¸¸¼ºÀ¯µ¹(±â)¿°
  • chronic meningoencephalitis
    ¸¸¼º¼ö¸·³ú¿°(¡­âÐØ¯Òàæú).
  • chronic motor or vocal tic disorder
    ¸¸¼º ¿îµ¿¼º ȤÀº À½¼ºÆ½ Àå¾Ö
  • chronic mountain sickness
    ¸¸¼º°í»êº´(¡­ÍÔߣܻ).
  • chronic myelocytic leukermia =CML
    ¸¸¼º°ñ¼ö(¼º)¹éÇ÷º´(¡­ÍéâÐàõÛÜúìÜ»).
  • chronic myelocytic leukermia =CML
    ¸¸¼º°ñ¼ö(¼º)¹éÇ÷º´(?Ë­ËàËÛËÑÌ´ËÓ).
  • chronic myelogenous leukemia
    ¸¸¼º°ñ¼ö¼º ¹éÇ÷º´.
  • chronic myelogenous leukemia
    ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
APSGN acute poststreptococcal glomerulonephritis
DGN diffuse glomerulonephritis
DGPG diffuse proliferative glomerulonephritis
DPGN diffuse proliferative glomerulonephritis
EGN experimental glomerulonephritis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
B CLL B cell chronic lymphocytic leukemia
B-CLL B type chronic lymphocytic leukaemia
CLL Chronic Lymphatic Leukaemia
CLL B-chronic lymphocytic leukaemia
CRF CHRONIC RENAL FAILURE
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • familial benign chronic pemphigus
    °¡Á·¼º ¾ç¼º ¸¸¼º õÆ÷â
  • following chronic infectious disease
    ¸¸¼º °¨¿° ÁúȯÀÇ ÃßÀû
  • pemphigus chronic vulgaris
    ¸¸¼º ½É»ó¼º õÆ÷â
    ÀÚ°¡ ¸é¿ª¼º ¼öÆ÷¼º ÁúȯÀ¸·Î¼­ ÁÖ·Î ÇÇºÎ¿Í Á¡¸·¿¡ ¹ß»ýÇÑ´Ù. Ư¡Àû ÀÚ°¡ Ç×üÀÇ ¸ñÇ¥ ÁöÁ¡Àº »óÇÇÀÇ ¼¼Æ÷°£±³ º¹ÇÕüÀÌ´Ù. ÀÌ·¯ÇÑ Á¶Á÷°ú ÀÚ°¡ Ç×ü°¡ ¹ÝÀÀÇϸé, ¼¼Æ÷ °áÇÕÀÌ ÆÄ±«µÇ¾î »óÆÐÀÇ ºÐ¸®°¡ ¾ß±âµÈ´Ù. À¯ÀüÀû ¿äÀÎÀÌ ÀÌ Áúȯ°ú °ü·Ã ÀÖ´Ù. ½É»ó¼º õÆ÷âÀÇ Ç¥ÇÇ ¹× Á¡¸· ¼Ò°ßÀº ÀϽÃÀûÀ̸ç, ¸¼Àº ¼ö¾×À¸·Î ä¿öÁø ¼Ò¼öÆ÷ ¹× ¼öÆ÷°¡ ³ªÅ¸³µ´Ù°¡ ÅÍÁüÀ¸·Î¼­ ±Ë¾çÀÌ µÇ´Âµ¥ ºÎºÐÀûÀ¸·Î´Â À¯¾àÇÑ ¸·À¸·Î µ¤¿©Áø °ÍÀ» º¼ ¼ö ÀÖ´Ù. ´ëºÎºÐÀÇ È¯ÀÚ´Â Áß³â ÀÌÈÄ¿¡ ³ªÅ¸³ªÁö¸¸ ¾î¸°À̳ª ÀþÀºÀÌ¿¡°Ôµµ ¹ß»ý ÇÒ ¼ö ÀÖ´Ù. ´ëºÎºÐÀÇ ÀÚ°¡ ¸é¿ª Áúȯ°ú ¸¶Âù°¡Áö·Î Ä¡·á´Â ÄÚ¸®Æ¼ÄÚ ½ºÅ×·ÎÀ̵带 ±¹¼Ò µµÆ÷ ¹× Àü½Å Åõ¿©ÇÏ´Â µî ¸é¿ª¾ïÁ¦Á¦¿¡ ÀÇÁ¸ÇÑ´Ù.
  • severe, painful, chronic arthritis
    ½ÉÇÑ ÅëÁõ¼º ¸¸¼º °üÀý¿°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
chronic idiopathic jaundice <syndrome> An inherited disorder (autosomal recessive) that is characterised by long-standing mild jaundice. This occurs secondary to an abnormality in the transport of bilirubin from the liver to the biliary system. This leads to an accumulation of bilirubin in the liver. Avoidance of alcohol and medications which can affect the liver is important.
Inheritance: autosomal recessive.
(27 Sep 1997)
chronic idiopathic xanthomatosis Vague or indefinite term for inherited abnormalities of lipid metabolism leading to xanthoma formation (e.g., primary familial xanthomatosis).
(05 Mar 2000)
chronic illness An illness that has persisted for a long period of time. It is a continuing disease process.
(12 Dec 1998)
chronic inflammation An inflammation that may begin with a relatively rapid onset or in a slow, insidious, and even unnoticed manner, tends to persist for several weeks, months, or years and has a vague and indefinite termination; results when the injuring agent (or products resulting from its presence) persists in the lesion, and the host's tissues respond in a manner (or to a degree) that is not sufficient to overcome completely the continuing effects of the injuring agent.
(05 Mar 2000)
chronic inflammatory demyelinating polyneuropathy An uncommon, acquired, demyelinating sensorimotor polyneuropathy, clinically characterised by insidious onset, and slow evolution, (either steady progression or stepwise), and chronic course; symmetrical weakness is a predominant symptom, often involving proximal leg muscles, accompanied by paresthesias, but not pain; CSF examination shows elevated protein, while electrodiagnostic studies reveal evidence of a demyelinating process, primarily conduction slowing rather than block; sometimes responds to prednisone.
(05 Mar 2000)
chronic inflammatory polyneuropathy <neurology, pathology> A disorder that involves the slow progressive (or recurrent) inflammation of multiple nerves. Loss of movement and sensation are common findings. The exact cause is related to an abnormal immune response.
The acute form of this illness is known as Guillain-Barre syndrome. Treatment often includes systemic corticosteroids or chemotherapeutic agents to suppress the immune system. Prognosis is variable.
Origin: Gr. Pathos = disease
(27 Sep 1997)
chronic interstitial hepatitis An obsolete term for cirrhosis of the liver.
(05 Mar 2000)
chronic interstitial hypertrophic neuropathy dejerine-Sottas disease
chronic interstitial salpingitis Salpingitis in which fibrosis or mononuclear cell infiltration involves all layers of the fallopian or eustachian tube.
Synonym: pachysalpingitis.
(05 Mar 2000)
chronic kidney failure Chronic renal failure represents a slow decline in kidney function over time. Chronic renal failure may be caused by a number of disorders which include long-standing hypertension, diabetes, congestive heart failure, lupus or sickle cell anaemia. If renal function declines to a low enough level (end-stage renal disease) kidney dialysis may be necessary. A sudden decline in renal function may be triggered by a number of acute disease processes.
Examples include sepsis (infection), shock, trauma, kidney stones, kidney infection, drug toxicity (aspirin or lithium), poisons or toxins (drug abuse) or after injection with an iodinated contrast dye (adverse effect). Both forms of renal failure result in a life-threatening metabolic derangement.
(27 Sep 1997)
chronic leukaemia A persistent cancer of the blood, usually of gradual onset and generally of slow progression. May be diagnosed by chance following a routine blood test and prior to the appearance of clinical symptoms.
Origin: Gr. Haima = blood
(13 Nov 1997)
chronic lymphadenoid thyroiditis <endocrinology> Inflammation of the thyroid gland without the formation of pus. Noninfectious nonbacterial thyroid inflammation.
(27 Sep 1997)
chronic lymphocytic leukaemia <haematology> A slowly progressing form of leukaemia, characterised by an increased number of the type of white blood cell known as lymphocytes. With about 3, 500 new cases occurring each year in the UK, it is the most common form of leukaemia and occurs predominantly in late middle age onwards. It has variable symptoms and course, but may be diagnosed by chance before the patient develops any clinical symptoms of disease.
Acronym: CLL
Origin: Gr. Haima = blood
(12 Jan 1998)
chronic lymphocytic thyroiditis <endocrinology> Inflammation of the thyroid gland without the formation of pus. Noninfectious nonbacterial thyroid inflammation.
(27 Sep 1997)
chronic malaria Malaria that develops after frequently repeated attacks of one of the acute forms, usually falciparum malaria; it is characterised by profound anaemia, enlargement of the spleen, emaciation, mental depression, sallow complexion, oedema of ankles, feeble digestion, and muscular weakness.
Synonym: limnaemia, malarial cachexia.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á